Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: A systematic review and meta-analysis

Tumor Biology

Volumn 35, Issue 6, 2014, Pages 5551-5560

  Ma, Xuelei ^a   Xiao, Zhilan ^a   Li, Xiaojun ^a   Wang, Fengtian ^a   Zhang, Jing ^a   Zhou, Rubai ^a   Wang, Junbo ^a   Liu, Lei ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Bone marrow; Circulating tumor cell; Metastasis; Prognosis; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER;

BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL DECISION MAKING; DISEASE FREE SURVIVAL; HUMAN; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SYSTEMATIC REVIEW;

ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; HUMANS; MALE; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSTATIC NEOPLASMS; PUBLICATION BIAS;

EID: 84904753867     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1731-5     Document Type: Review

References (52)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002;2:389-96. (Pubitemid 37328952)
3. Cooner WH, Mosley BR, Rutherford Jr CL, Beard JH, Pond HS, Terry WJ, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol. 1990;143:1144-6.
4. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsymethods in the investigation of prostate cancer: a systematic review. J Urol. 2006;175:1605-12.
5. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. Eau guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61-71.
6. Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869;14:146-9.
7. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353:793-802. (Pubitemid 41215488)
8. Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res. 2012;18:5701-10.
9. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26:3213-3221.
10. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:1556-63.
11. Olmos D, Arkenau H, Ang JE, Ledaki I, Attard G, Carden CP, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol. 2009;20:27-33.
12. Pantel K, Izbicki J, Passlick B, Angstwurm M, Haussinger K, Thetter O, et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet. 1996;347:649-53. (Pubitemid 26076131)
13. Pierga J-Y, Bidard F-C, Mathiot C, Brain E, Delaloge S, Giachetti S, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:7004-10.
14. Rack BK, Schindlbeck C, Schneeweiss A, Hilfrich J, Lorenz R, Beckmann MW, Pantel K, Lichtenegger W, Sommer HL, Janni WJ. Prognostic relevance of circulating tumor cells (CTCS) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: the german success-trial. 2008.
15. Ghossein R, Rosai J, Scher H, Seiden M. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic. Urology. 1997;4295:100-5.
16. Goodman OB, Fink LM, Symanowski JT, Wong B, Grobaski B, Pomerantz D, et al. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiol Biomark Prev. 2009;18:1904-13.
17. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232-7. (Pubitemid 46606398)
18. Hara N, Kasahara T, Kawasaki T. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. Clin Cancer Res. 2002;8:1794-9. (Pubitemid 34633737)
19. Joung JAEY, Cho KSU, Kim JEUN, Seo HOK, Chung J, Park WSEO, et al. Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence in high-risk prostate cancer. J Surg Oncol. 2010;101:145-8.
20. Lembessis P, Msaouel P. Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts. Clin Chem Lab Med. 2007;45:1488-94.
21. Moreno J, Miller M, Gross S, Allard W. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology. 2005;65:713-8. (Pubitemid 40523005)
22. Okegawa T, Nutahara K, Higashihara E. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic. J Urol. 2008;180:1342-7.
23. Okegawa T, Nutahara K, Higashihara E. Original article: clinical investigation association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory. Int J Urol. 2010;17:466-75.
24. Okegawa T, Nutahara K, Higashihara E. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J Urol. 2009;181:1091-7.
25. Olsson CA, Vries GMDE, Raffo AJ, Benson MC, Otoole K, Cao Y, et al. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J Urol. 1996;155:1557-62. (Pubitemid 26126948)
26. Scher HI, Jia X, Bono JSD, Fleisher M, Pienta KJ, Raghavan D, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer : a reanalysis of IMMC38 trial data. Lancet Oncol. 2009;10:233-9.
27. Strijbos MH, Gratama JW, Schmitz PIM, Rao C, Onstenk W, Doyle GV, et al. Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. Eur J Cancer. 2010;46:2027-35.
28. Thomas C, Wiesner C, Melchior SW, Schmidt F, Gillitzer R, Thüroff JW, et al. Urokinase-plasminogen-activator receptor expression in desseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer. Int Br J Urol. 2008;104:29-34.
29. Weckermann D, Polzer B, Ragg T, Blana A, Bertz S, Harzmann R, et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol. 2009;27:1549-56.
30. Thalgott M, Rack B, Maurer T, Souvatzoglou M, Eiber M, Kreß V, et al. Detection of circulating tumor cells in different stages of prostate cancer. J Cancer Res Clin Oncol. 2013;139:755-63.
31. Resel Folkersma L, San José Manso L, Galante Romo I, Moreno Sierra J, Olivier Gómez C. Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer. Urology. 2012;80:1328-32.
32. Wood Jr DP, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15:3451-7. (Pubitemid 27527717)
33. Berg A, Berner A, Lilleby W, Bruland ØS, Foss SD. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int J Cancer. 2007;120:1603-9. (Pubitemid 46399343)
34. Gewanter R, Katz A, Olsson C. RT-PCR for PSA as a prognostic factor for patients with clinically localized prostate cancer treated with radiotherapy. Urology. 2003;4295:967-71. (Pubitemid 36547740)
35. Mejean A, Vona G, Naplas B. Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. J Urol. 2000;163:2022-9. (Pubitemid 30366805)
36. Oefelein M, Ignatoff J. Clinical and molecular followup after radical retropubic prostatectomy. J Urol. 1999;162:307-10.
37. Shariat S, Gottenger E, Nguyen C. Reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res. 2002;62:5974-9. (Pubitemid 35204762)
38. Tierney JF, Stewart L, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
39. Bianco Jr FJ, Powell IJ, Cher ML, Wood Jr DP. Presence of circulating prostate cancer cells in African American males adversely affects survival. Urologic Oncology: Seminars and Original Investigations, Elsevier, 2002, 7, pp 147-152.
40. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemporary Clinical Trials. 2007;28:105-14. (Pubitemid 44937874)
41. Easterbrook PJ, Gopalan R, Berlin JA, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867-72.
42. Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, et al. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res. 2009;15:677-83.
43. Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13:2023-9. (Pubitemid 46649868)
44. Doyen J, Alix-Panabières C, Hofman P, Parks SK, Chamorey E, Naman H, et al. Circulating tumor cells in prostate cancer: a potential surrogate marker of survival. Critical Rev Oncol/Hematol. 2012;81:241-56.
45. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450:1235-9.
46. Groot Koerkamp B, Rahbari NN, Buchler MW, Koch M, Weitz J. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Annals Surg Oncol. 2013;20:2156-65.
47. Ma X-L, Xiao Z-L, Liu L, Liu X-X, Nie W, Li P, et al. Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer. Asian Pac J Cancer Prev. 2012;13:1137-44.
48. Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful? Prognostic variables in node-negative and node-positive breast cancer, Breast Cancer Res Tr. Kluwer Academic Publishers, Netherlands, 1998, 395-409.
49. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008;8:329-40. (Pubitemid 351596394)
50. Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer cell. 2013;23:573-81.
51. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339:580-4.
52. Hou J-M, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al. Clinical significance andmolecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012;30:525-32.